Consistent positive trends across multiple secondary and exploratory clinical endpoints were also observed, in addition to a potential biological effect of prasinezumab on MRI ... Parkinson's disease, ...

Consistent positive trends across multiple secondary and exploratory clinical endpoints were also observed, in addition to a potential biological effect of prasinezumab on MRI biomarkers ... Alzheimer ...

New trontinemab data continue to support rapid and deep, dose-dependent reduction of amyloid plaques in Phase Ib/IIa Brainshuttle AD study Data on the Elecsys® pTau181 plasma test demonstrate potentia ...

Older adults with ADHD are at higher risk of age-related dementias like Alzheimer's disease, and an international team of ...

A new CRISPR-based technology, called RIDE, is a leap forward for this trail-blazing technology. With the precision of a scalpel sharp enough to rewrite the very code of life, researchers have used it ...

Advanced imaging techniques are crucial for unraveling these complexities, offering insights into disease mechanisms ... Medical Imaging, PET, MRI, Alzheimer's, Parkinson’s, Huntington’s, Multiple ...

The number of people who have the gene that causes Huntington's disease in Northern Scotland has been accurately counted for ...

Mouse studies demonstrated that newly generated neurons connect with brain networks responsible for motor control.

AMT-130 is administered through magnetic resonance imaging-guided, convection-enhanced stereotactic neurosurgical delivery into the striatum.

Breakthrough Therapy designation based on clinical evidence from Phase I/II trials showing meaningful slowing of disease progression ~~ ...

Gene therapy developer uniQure shares soared 46% in premarket trading after its treatment for Huntington's disease received breakthrough therapy designation from the Food and Drug Administration.